Related Experiment Video
Updated: Jun 8, 2026
05:16
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
[Anaemia in chronic heart failure].
1III. interní klinika 1. Iékarské fakulty UK a VFN Praha. jhradec@vfn.cz
Vnitrni Lekarstvi
|September 18, 2010
Summary
Anemia in chronic heart failure and kidney disease is common and increases mortality risk. While erythropoiesis-stimulating agents can improve anemia, the TREAT study showed increased cerebrovascular events, highlighting safety concerns.
Area of Science:
- Nephrology
- Cardiology
- Hematology
Context:
- Anemia frequently co-exists with chronic heart failure (CHF) and chronic kidney disease (CKD).
- Anemia in these conditions is a significant predictor of increased morbidity and mortality.
- Multifactorial causes include reduced erythropoietin production, iron deficiency, and fluid retention.
Purpose:
- To review the role of anemia in CHF and CKD and discuss treatment strategies.
- To evaluate the efficacy and safety of erythropoiesis-stimulating agents (ESAs) in managing anemia in these patient populations.
- To highlight findings from key clinical trials, including the TREAT and RED-HF studies.
Summary:
- Treatment strategies involve stimulating erythropoiesis with ESAs (e.g., darbepoetin alfa) and iron substitution, preferably intravenous.
- Previous small-scale studies suggested ESAs improved exertion tolerance and quality of life in CHF patients.
- The TREAT study (n>4000) found darbepoetin alfa did not impact cardiovascular/renal events but increased cerebrovascular events in CKD patients with diabetes.
Impact:
- Findings raise concerns about ESA safety, particularly regarding cerebrovascular events.
- The ongoing RED-HF study aims to clarify the impact of anemia treatment on patient prognosis in CHF.
- Optimal management of anemia in CHF and CKD requires careful consideration of risks and benefits.
Related Concept Videos
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...